Curanex Pharmaceuticals Inc Common Stock (CURX) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | -15.03K | 0 | 15.03K | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 0 | 15.03K | 0 | -15.03K | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - |
| Operating Expenses | 3.18M | 3.09M | 951.33K | 57.66K | 137.45K | 44.2K |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 927.2K | 784.24K | 273.85K | 57.66K | 137.45K | 44.2K |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 2.26M | 2.31M | 677.47K | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -3.18M | -3.09M | -951.33K | -57.66K | -137.45K | -44.2K |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | -2215.98% | - | - | -30.45% | - | - |
| EBITDA | -3.15M | -3.06M | -935.89K | -42.63K | -122.82K | -44.2K |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | -2463.38% | - | - | 3.56% | - | - |
| D&A (Non-Cash Add-back) | 35.04K | 34.29K | 15.44K | 15.03K | 14.63K | 0 |
| EBIT | 0 | 1.14M | -949.97K | -57.26K | -136.23K | -44.2K |
| Net Interest Income | 0 | 8.54K | -4.09K | -3.09K | -1.36K | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | -17.07K | 4.09K | 3.09K | 1.36K | 0 |
| Other Income/Expense | 33.13K | 19.52K | -2.73K | -2.69K | -131 | 0 |
| Pretax Income | -3.15M | -3.07M | -954.06K | -60.35K | -137.58K | -44.2K |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -3.15M | -3.07M | -954.06K | -60.35K | -137.58K | -44.2K |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | -2189.69% | - | - | -36.53% | - | - |
| Net Income (Continuing) | -3.15M | -3.07M | -954.06K | -60.35K | -137.58K | -44.2K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.11 | -0.12 | -0.04 | -0.00 | -0.01 | -0.00 |
| EPS Growth % | - | - | - | - | - | - |
| EPS (Basic) | -0.11 | -0.12 | -0.04 | -0.00 | -0.01 | -0.00 |
| Diluted Shares Outstanding | 28.34M | 25.5M | 25.6M | 27.75M | 27.75M | 42M |
| Basic Shares Outstanding | 28.34M | 25.5M | 25.6M | 27.75M | 27.75M | 27.75M |
| Dividend Payout Ratio | - | - | - | - | - | - |